Albiotic 330 mg / 100 mg Intramammary Solution

Country: Bretland

Tungumál: enska

Heimild: VMD (Veterinary Medicines Directorate)

Virkt innihaldsefni:

Lincomycin, Neomycin

Fáanlegur frá:

Huvepharma N.V.

INN (Alþjóðlegt nafn):

Lincomycin, Neomycin

Lyfjaform:

Intramammary solution

Gerð lyfseðils:

POM-V - Prescription Only Medicine – Veterinarian

Meðferðarhópur:

Cattle

Lækningarsvæði:

Antimicrobial intramammary

Leyfisstaða:

Authorized

Leyfisdagur:

2000-01-04

Vara einkenni

Revised: August 2019
AN: 01677/2018
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Albiotic 330 mg / 100 mg Intramammary Solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES
per syringe (10 ml)
Lincomycin (as Lincomycin hydrochloride)
330 mg
Neomycin (as Neomycin sulphate)
100 mg
EXCIPIENTS
Disodium edetate
5 mg
For the full list of excipients, see Section 6.1
3.
PHARMACEUTICAL FORM
Intramammary solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Lactating cow
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of mastitis in lactating cattle. The product is
effective
against Staphylococcus species (both penicillinase and
non-penicillinase
producers)
including
Staphylococcus
aureus,
Streptococcus
species
including
Streptococcus
agalactiae,
Streptococcus
dysgalactiae
and
Streptococcus uberis, and coliform bacteria including Escherichia
coli.
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
Revised: August 2019
AN: 01677/2018
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
None
ii.
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Avoid contact with the solution. Wash hands and any exposed skin
immediately after use.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None known
4.7
USE DURING PREGNANCY, LACTATION, OR LAY
No restrictions.
4.8
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
This
product
should
not
be
used
concomitantly
with
macrolides
e.g.
erythromycin, because lincomycin and the macrolides antagonise each
other at the site of action, the 50S ribosomal sub-unit.
4.9
AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
Dosage: infuse one syringe (10 ml. product) into each affected
quarter.
Repeat this treatment immediately after each of the next two 12 hourly
milkings, to give a total of three infusions per infected quarter.
Administration: by intramammary infusion only, taking a